⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMRN News
BioMarin Pharmaceuticals Inc
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
prnewswire.com
BMRN
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
prnewswire.com
BMRN
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
prnewswire.com
BMRN
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
prnewswire.com
BMRN